US 10870854
Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment
granted A61KA61K31/7088A61K45/06
Quick answer
US patent 10870854 (Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment) held by The Board of Regents of the University of Texas System expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/7088, A61K45/06, A61K9/127, A61K9/51